Capivasertib vs NTQ1062
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: AKT (inhibitor) · full HR+/HER2- Metastatic Breast Cancer pipeline
Capivasertib
Marketed by AstraZeneca and partners
NCT04305496 · Phase 3 · active, not recruiting
Patients were randomized to capivasertib or matching placebo, both added to fulvestrant, with participants, care providers, investigators and outcomes assessors all masked. With 355 vs 353 patients in the global cohort, the primary endpoint of progression-free survival was significantly longer with capivasertib (hazard ratio 0.60, 95% CI 0.51 to 0.71, p<0.001).
Next expected readout: December 2026 · NCT05563220 (registry estimate)
Reported efficacy
Progression Free Survival: Overall Population (Months) in the Global Cohort (Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.); Progression Free Survival: Overall Population (Percentage) in the Global Cohort (Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.); Progression Free Survival: Altered Population (Months) in the Global Cohort (Assessed every 8 weeks for the first 2 years following objective disease progression or treatment discontinuation and then every 12 weeks.); Progression Free Survival: Altered Population (Percentage) in the Global Cohort (Assessed every 8 weeks for the first 2 years following objective disease progression or treatment discontinuation and then every 12 weeks.); Progression Free Survival: Overall Population (Months) in the China Cohort (Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.); Progression Free Survival: Overall Population (Percentage) in the China Cohort (Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.); Progression Free Survival: Altered Population (Months) in the China Cohort (Assessed every 8 weeks for the first 2 years following objective disease progression or treatment discontinuation and then every 12 weeks.); Progression Free Survival: Altered Population (Percentage) in the China Cohort (Assessed every 8 weeks for the first 2 years following objective disease progression or treatment discontinuation and then every 12 weeks.): Progression Free Survival: Overall Population (Months) in the Global Cohort (Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.): Capivasertib + Fulvestrant (Global + China Cohort) 7.2 Months (95% CI 5.5 to 7.4) vs Placebo + Fulvestrant (Global + China Cohort) 3.6 Months (95% CI 2.8 to 3.7) (met)
Result source: NCT04305496
NTQ1062
Developed by Sino Biopharmaceutical
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: August 2028 · NCT07393321 (registry estimate)
No aligned efficacy figure on record for this race.
Results for HR+/HER2- Metastatic Breast Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Capivasertib | NTQ1062 |
|---|---|---|
| PFS, median | 7.2 vs 3.6+3.6 vs placeboNCT043054964 other results
| —Trial running · NCT07393321 |
| OS, median | 32.8NCT01625286 | —Trial running · NCT07393321 |
| ORR | —Trial running · NCT04305496 | —Trial running · NCT07393321 |
| Clinical benefit rate | —Trial running · NCT04305496 | —Trial running · NCT07393321 |
PFS, median
- Capivasertib
- 7.2 vs 3.6+3.6 vs placeboNCT04305496
4 other results
- 7.3 vs 3.1 NCT04305496
- 6.9 vs 2.8 NCT04305496
- 5.7 vs 1.9 NCT04305496
- 10.9 vs 8.4 NCT01625286
- NTQ1062
- —Trial running · NCT07393321
OS, median
- Capivasertib
- 32.8NCT01625286
- NTQ1062
- —Trial running · NCT07393321
ORR
- Capivasertib
- —Trial running · NCT04305496
- NTQ1062
- —Trial running · NCT07393321
Clinical benefit rate
- Capivasertib
- —Trial running · NCT04305496
- NTQ1062
- —Trial running · NCT07393321
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
NTQ1062: no structured comparison results are available for HR+/HER2- Metastatic Breast Cancer.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Capivasertib: 4 of 4 rows · NTQ1062: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Capivasertib |
|---|---|
| Dropout rate | —Capi (China Cohort)a NCT04305496 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 10 more results—Capi (Global Cohort) NCT04305496 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 50%640 mg bd NCT01625286 · Phase 1/2 · combination —640 mg bd NCT01625286 · Phase 1/2 · combination 50%560 mg bd NCT01625286 · Phase 1/2 · combination 100%480 mg bd NCT01625286 · Phase 1/2 · combination 100%400 mg bd NCT01625286 · Phase 1/2 · combination —400 mg bd NCT01625286 · Phase 1/2 · combination 100%360 mg bd NCT01625286 · Phase 1/2 · combination —360 mg bd NCT01625286 · Phase 1/2 · combination 25.9%Part B AZD5363 NCT01625286 · Phase 1/2 · combination |
| Discontinued due to AEs | —Capi (China Cohort)a NCT04305496 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 10 more results—Capi (Global Cohort) NCT04305496 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 0%640 mg bd NCT01625286 · Phase 1/2 · combination —640 mg bd NCT01625286 · Phase 1/2 · combination 0%560 mg bd NCT01625286 · Phase 1/2 · combination 16.7%480 mg bd NCT01625286 · Phase 1/2 · combination 0%400 mg bd NCT01625286 · Phase 1/2 · combination —400 mg bd NCT01625286 · Phase 1/2 · combination 0%360 mg bd NCT01625286 · Phase 1/2 · combination —360 mg bd NCT01625286 · Phase 1/2 · combination 3.7%Part B AZD5363 NCT01625286 · Phase 1/2 · combination |
| Serious AEs | 28.2%Capi (China Cohort)a NCT04305496 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 10 more results16.1%Capi (Global Cohort) NCT04305496 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 —640 mg bd NCT01625286 · Phase 1/2 · combination 37.5%640 mg bd NCT01625286 · Phase 1/2 · combination 25%560 mg bd NCT01625286 · Phase 1/2 · combination 66.7%480 mg bd NCT01625286 · Phase 1/2 · combination —400 mg bd NCT01625286 · Phase 1/2 · combination 14.3%400 mg bd NCT01625286 · Phase 1/2 · combination —360 mg bd NCT01625286 · Phase 1/2 · combination 0%360 mg bd NCT01625286 · Phase 1/2 · combination 24.1%Part B AZD5363 NCT01625286 · Phase 1/2 · combination |
| Most frequent reported AEs | a diarrhoea 60.6% (placebo 11.3%) hyperglycaemia 57.7% (placebo 17.7%) anaemia 31% (placebo 17.7%) NCT04305496 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 7 more resultsdiarrhoea 71.8% (placebo 11.3%) nausea 34.4% (placebo 3.2%) rash 21.7% (placebo 6.5%) NCT04305496 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 640 mg bd diarrhoea 87.5% (placebo 27.3%) asthenia 62.5% (placebo 12.7%) dizziness 62.5% (placebo 7.3%) NCT01625286 · Phase 1/2 · combination 560 mg bd diarrhoea 91.7% (placebo 27.3%) nausea 66.7% (placebo 23.6%) anaemia 50% (placebo 27.3%) NCT01625286 · Phase 1/2 · combination 480 mg bd diarrhoea 100% (placebo 27.3%) nausea 83.3% (placebo 23.6%) vomiting 66.7% (placebo 14.5%) NCT01625286 · Phase 1/2 · combination 400 mg bd asthenia 85.7% (placebo 12.7%) diarrhoea 85.7% (placebo 27.3%) myalgia 42.9% (placebo 21.8%) NCT01625286 · Phase 1/2 · combination 360 mg bd diarrhoea 100% (placebo 27.3%) alopecia 60% (placebo 49.1%) nausea 60% (placebo 23.6%) NCT01625286 · Phase 1/2 · combination diarrhoea 75.9% (placebo 27.3%) alopecia 51.9% (placebo 49.1%) nausea 38.9% (placebo 23.6%) NCT01625286 · Phase 1/2 · combination |
Notes
- aPopulation comparability has not been reviewed for 9 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Capivasertib
show 4 more results
show 11 more results
show 5 more results
show 11 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Capivasertib's landscape · NTQ1062's landscape